- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Medincell SA (MEDCL)
Track today's live Medincell (MEDCL) share price, performance and key data on this page with our current Paris:MEDCL stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Medincell share price on the Paris exchange. Use the dropdown to switch exchange for the MEDCL share price, head to our technical summary section, which provides analysis on Medincell share price buy/sell indicators using real-time data (or discuss the Medincell (MEDCL) stock price today with other investors in the Medincell EPA share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current EPA:MEDCL share price (ISIN: FR0004065605) to enhance your trading decisions with our free investment tools and resources.
What Is the Medincell SA Share Price Today?
The Medincell share price today is 26.36.
What Is the Stock Symbol for Medincell SA
The stock symbol (or 'ticker') for Medincell SA is "MEDCL."
What Stock Exchange Does Medincell SA Trade On?
Medincell SA is listed and trades on the Paris stock exchange.
Is Medincell SA a Good Stock to Buy?
Determining whether Medincell (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current EPA:MEDCL share price (ISIN: FR0004065605) to enhance your trading decisions with our free investment tools and resources.
What Is the Medincell SA Share Price Today?
The Medincell share price today is 26.36.
What Is the Stock Symbol for Medincell SA
The stock symbol (or 'ticker') for Medincell SA is "MEDCL."
What Stock Exchange Does Medincell SA Trade On?
Medincell SA is listed and trades on the Paris stock exchange.
Is Medincell SA a Good Stock to Buy?
Determining whether Medincell (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
26.36
+0.10(+0.38%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
25.70
26.64
52 wk Range
19.69
38.66
MEDCL is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
25.7026.64
52 wk Range
19.6938.66
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
MEDCL Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
35.51
Upside
+34.72%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Liquid assets exceed short term obligations
Why is Medincell stock plunging today?- Investing.com
Why is Teva Pharma stock surging today?- Investing.com
Medincell SA receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Why is Teva Pharma stock surging today?
- Investing.com
- Medincell SA receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy
Analyst Ratings
8 Buy
1 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 35.51
(+34.72% Upside)
Earnings
Latest Release
02/09/2026
EPS / Forecast
-- / -0.14
Revenue / Forecast
-- / 6.8M
Compare MEDCL to Peers and Sector
Metrics to compare | MEDCL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMEDCLPeersSector | |
|---|---|---|---|---|
P/E Ratio | −30.3x | 18.7x | −0.3x | |
PEG Ratio | 0.59 | 0.03 | 0.00 | |
Price/Book | 309.0x | 2.4x | 2.6x | |
Price / LTM Sales | 39.0x | 2.4x | 2.8x | |
Upside (Analyst Target) | 34.7% | 54.5% | 66.4% | |
Fair Value Upside | Unlock | 2.5% | 9.1% | Unlock |
MedinCell S.A. engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France. The company offers UZEDY, a subcutaneous risperidone for the treatment of schizophrenia. It also develops mdc-TJK, a subcutaneous injection, which is in NDA stage for the treatment of schizophrenia; and mdc-CWM, a sustained-release formulation of celecoxib, which is in Phase III clinical trial for the treatment and reduction of post-operative pain and inflammation. In addition, the company engages in the development of products in preclinical stage, including mdc-WWM for contraception; mdc-STM for the treatment of malaria; and mdc-AbbVie-1. It has strategic collaborations with TEVA, AIC, ABBVIE, Unitaid, and Gates Foundation. The company was incorporated in 2003 and is headquartered in Jacou, France.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Medincell (Paris: MEDCL) Share Price Today?
The Medincell stock price today is 26.36 EUR.
What Stock Exchange Does Medincell (MEDCL) Trade On?
Medincell is listed and trades on the Paris Stock Exchange.
What Is the Ticker (Stock Symbol) for Medincell?
The stock symbol (also called a 'ticker') for Medincell is "MEDCL."
What Is the Current Medincell Market Capitalisation?
As of today, Medincell (Paris: MEDCL) market cap is 946.63M EUR.
What Is Medincell's (MEDCL) Earnings Per Share (TTM)?
The Medincell EPS is currently -0.94 (Trailing Twelve Months).
When Is the Next Medincell Earnings Date?
Medincell's next earnings report will be released on 09/12/2026.
Is MEDCL a Buy or Sell From a Technical Analyst Perspective?
Based on today's Medincell moving averages and other technical indicators, the daily buy/sell signal for MEDCL stock is Neutral.
How Many Times Has Medincell Stock Split?
Medincell has split 0 times. (See the MEDCL stock split history page for full effective split date and price information.)
How Many Employees Does Medincell Have?
Medincell has 141 employees, based on their latest Companies House report.
What is the current trading status of Medincell (Paris: MEDCL)?
As of 01/11/2026, Medincell (MEDCL) is trading at a share price of 26.36 EUR, with a previous close of 26.36 EUR. The stock has fluctuated within a day range of 25.70 EUR to 26.64 EUR, while its 52-week range spans from 19.69 EUR to 38.66 EUR.
What Is Medincell (MEDCL) Price Target According to Analysts?
The average 12-month price target for Medincell is 35.51 EUR, with a high estimate of 41 EUR and a low estimate of 31 EUR. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +34.72% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.